Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | unknown | Phase 2 | 123 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 140 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 7, 2020 | clinicaltrials |
| NCT04376957 | Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma | unknown | N/A | 60 | Hamilton Health Sciences CorporationOTHER | 0 | May 6, 2020 | clinicaltrials |
| NCT04364724 | CTFEA Myeloma Study | unknown | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 28, 2020 | clinicaltrials |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2020 | clinicaltrials |
| NCT04127916 | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) | unknown | — | 40 | Samsung Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | unknown | Phase 2 | 250 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03633045 | Observational Study of Ibrutinib Use in CLL | unknown | — | 70 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04260490 | Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.(MYELODOM) | unknown | — | 600 | Centre Hospitalier Universitaire de la GuadeloupeOTHER | 2 | Feb 7, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04109872 | Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. | unknown | — | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02267915 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT(MAN2) | unknown | Phase 2 | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03847727 | Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | unknown | — | 112 | Pirogov Russian National Research Medical UniversityOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00505999 | Etiology of Multiple Myeloma: A Case-Control Study | unknown | — | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04212858 | Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma | unknown | N/A | 100 | Assiut UniversityOTHER | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03720496 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy | unknown | Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04173455 | Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma | unknown | Phase 1 | 46 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04169932 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03702088 | Place of the Hevylite Test in the Evaluation of MRD in Myeloma | unknown | — | 124 | University Hospital, MontpellierOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04122092 | Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma(EUCADD) | unknown | — | 100 | Shanghai Changzheng HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04163302 | Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04154228 | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04152577 | R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL | unknown | Phase 4 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02387879 | A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR | unknown | — | 500 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2020source: clinicaltrials